Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib.

Lee SE, Choi SY, Bang JH, Kim SH, Jang EJ, Byeun JY, Park JE, Jeon HR, Oh YJ, Kim HJ, Kim YK, Park JS, Jeong SH, Kim SH, Zang DY, Oh S, Koo DH, Kim H, Do YR, Kwak JY, Kim JA, Kim DY, Mun YC, Mauro MJ, Kim DW.

Am J Hematol. 2013 Jun;88(6):449-54. doi: 10.1002/ajh.23427. Epub 2013 Mar 28.

PMID:
23440689
[PubMed - indexed for MEDLINE]
2.

Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.

Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, Gardembas M, Etienne G, Réa D, Roy L, Escoffre-Barbe M, Guerci-Bresler A, Tulliez M, Prost S, Spentchian M, Cayuela JM, Reiffers J, Chomel JC, Turhan A, Guilhot J, Guilhot F, Mahon FX.

J Clin Oncol. 2014 Feb 10;32(5):424-30. doi: 10.1200/JCO.2012.48.5797. Epub 2013 Dec 9.

PMID:
24323036
[PubMed - indexed for MEDLINE]
3.

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, Dang P, Goyne JM, Slader C, Filshie RJ, Mills AK, Melo JV, White DL, Grigg AP, Hughes TP.

Blood. 2013 Jul 25;122(4):515-22. doi: 10.1182/blood-2013-02-483750. Epub 2013 May 23.

PMID:
23704092
[PubMed - indexed for MEDLINE]
Free Article
5.

Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.

Branford S, Yeung DT, Ross DM, Prime JA, Field CR, Altamura HK, Yeoman AL, Georgievski J, Jamison BA, Phillis S, Sullivan B, Briggs NE, Hertzberg M, Seymour JF, Reynolds J, Hughes TP.

Blood. 2013 May 9;121(19):3818-24. doi: 10.1182/blood-2012-10-462291. Epub 2013 Mar 20.

PMID:
23515925
[PubMed - indexed for MEDLINE]
Free Article
6.

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.

Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Bartley PA, Slader C, Field C, Dang P, Filshie RJ, Mills AK, Grigg AP, Melo JV, Hughes TP.

Leukemia. 2010 Oct;24(10):1719-24. doi: 10.1038/leu.2010.185. Epub 2010 Sep 2.

PMID:
20811403
[PubMed - indexed for MEDLINE]
7.

Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.

Hess G, Bunjes D, Siegert W, Schwerdtfeger R, Ledderose G, Wassmann B, Kobbe G, Bornhäuser M, Hochhaus A, Ullmann AJ, Kindler T, Haus U, Gschaidmeier H, Huber C, Fischer T.

J Clin Oncol. 2005 Oct 20;23(30):7583-93.

PMID:
16234522
[PubMed - indexed for MEDLINE]
Free Article
8.

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O, Blanchet O, Marit G, Gluckman E, Reiffers J, Gardembas M, Mahon FX.

Blood. 2007 Jan 1;109(1):58-60. Epub 2006 Sep 14.

PMID:
16973963
[PubMed - indexed for MEDLINE]
Free Article
9.

Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission.

Carella AM, Lerma E.

Ann Hematol. 2007 Oct;86(10):749-52. Epub 2007 Jun 19.

PMID:
17576558
[PubMed - indexed for MEDLINE]
10.

Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic myelogenous leukemia.

Ishikawa I, Kato C, Harigae H, Sugawara T, Tomiya Y, Yamada M, Ishizawa K, Kameoka J, Miyamura K, Sasaki T.

Tohoku J Exp Med. 2006 Dec;210(4):355-63.

PMID:
17146202
[PubMed - indexed for MEDLINE]
Free Article
11.

Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients.

Cerrano M, Crisà E, Pregno P, Aguzzi C, Riccomagno P, Boccadoro M, Ferrero D.

Am J Hematol. 2013 Oct;88(10):838-42. doi: 10.1002/ajh.23501. Epub 2013 Jul 23.

PMID:
23757199
[PubMed - indexed for MEDLINE]
12.

Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response.

Yhim HY, Lee NR, Song EK, Yim CY, Jeon SY, Shin S, Kim JA, Kim HS, Cho EH, Kwak JY.

Leuk Res. 2012 Jun;36(6):689-93. doi: 10.1016/j.leukres.2012.02.011. Epub 2012 Mar 5.

PMID:
22398220
[PubMed - indexed for MEDLINE]
13.

Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature.

Guastafierro S, Falcone U, Celentano M, Coppola M, Ferrara MG, Sica A.

Leuk Res. 2009 Aug;33(8):1079-81. doi: 10.1016/j.leukres.2008.11.027. Epub 2009 Jan 22. Review.

PMID:
19167064
[PubMed - indexed for MEDLINE]
14.

Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.

Koh Y, Kim I, Yoon SS, Kim BK, Kim DY, Lee JH, Lee KH, Park E, Kim HJ, Sohn SK, Joo YD, Kim SJ, Chung J, Shin HJ, Kim SH, Kim CS, Song HS, Kim MK, Hyun MS, Ahn JS, Jung CW, Park S; Korean Society of Hematology CML working party.

Ann Hematol. 2010 Jul;89(7):725-31. doi: 10.1007/s00277-010-0910-8. Epub 2010 Feb 24.

PMID:
20179930
[PubMed - indexed for MEDLINE]
15.

Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib.

Mizoguchi I, Yoshimoto T, Katagiri S, Mizuguchi J, Tauchi T, Kimura Y, Inokuchi K, Ohyashiki JH, Ohyashiki K.

Cancer Sci. 2013 Sep;104(9):1146-53. doi: 10.1111/cas.12216. Epub 2013 Jul 9.

PMID:
23758044
[PubMed - indexed for MEDLINE]
16.

A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.

Press RD, Galderisi C, Yang R, Rempfer C, Willis SG, Mauro MJ, Druker BJ, Deininger MW.

Clin Cancer Res. 2007 Oct 15;13(20):6136-43.

PMID:
17947479
[PubMed - indexed for MEDLINE]
Free Article
17.

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.

Müller MC, Gattermann N, Lahaye T, Deininger MW, Berndt A, Fruehauf S, Neubauer A, Fischer T, Hossfeld DK, Schneller F, Krause SW, Nerl C, Sayer HG, Ottmann OG, Waller C, Aulitzky W, le Coutre P, Freund M, Merx K, Paschka P, König H, Kreil S, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.

Leukemia. 2003 Dec;17(12):2392-400.

PMID:
14523462
[PubMed - indexed for MEDLINE]
18.

Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.

Iacobucci I, Saglio G, Rosti G, Testoni N, Pane F, Amabile M, Poerio A, Soverini S, Bassi S, Cilloni D, Bassan R, Breccia M, Lauria F, Izzo B, Merante S, Frassoni F, Paolini S, Montefusco E, Baccarani M, Martinelli G; GIMEMA Working Party on Chronic Myeloid Leukemia.

Clin Cancer Res. 2006 May 15;12(10):3037-42.

PMID:
16707599
[PubMed - indexed for MEDLINE]
Free Article
19.

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.

Palandri F, Castagnetti F, Testoni N, Luatti S, Marzocchi G, Bassi S, Breccia M, Alimena G, Pungolino E, Rege-Cambrin G, Varaldo R, Miglino M, Specchia G, Zuffa E, Ferrara F, Bocchia M, Saglio G, Pane F, Alberti D, Martinelli G, Baccarani M, Rosti G; GIMEMA Working Party on Chronic Myeloid Leukemia.

Haematologica. 2008 Dec;93(12):1792-6. doi: 10.3324/haematol.13068. Epub 2008 Oct 6.

PMID:
18838477
[PubMed - indexed for MEDLINE]
Free Article
20.

Second-generation tyrosine kinase inhibitors combined with stem cell transplantation in patients with imatinib-refractory chronic myeloid leukemia.

Zhao Y, Luo Y, Shi J, Cai Z, Huang H.

Am J Med Sci. 2014 Jun;347(6):439-45. doi: 10.1097/MAJ.0000000000000186.

PMID:
24553398
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk